Products & Services Investor relations
About Cerep News Events & MeetingsContacts Downloads FAQs
Cerep home
Your data onlineCatalog online
Home > Investors relations> News & events > Press releases
Press releases
Risk Disclosure
These press releases are provided for your convenience only and are not necessarily updated.
They may contain forward-looking information which is subject to risks and uncertainties that
could cause the actual results to differ materially. Factors that may affect future operations
and business of the company are described in the prospectus relating to the company’s public
offering or in the company’s annual report.

2010 2009 2008 2007 2006 2005 2004-1998
November, 12
 3rd Quarter 2009 consolidated sales revenues
October, 13
 Cerep grants a BioPrint® evaluation licence to Roche
August, 28
 Cerep announces consolidated results for the first half 2009
June, 17
 Cerep and Servier establish a new collaboration agreement for drug discovery and lead optimization
June, 15
 Cerep announces kinase profiling agreement with Lilly
May, 4
 First quarter 2009 sales revenues
April, 28
 PerkinElmer and Cerep announce expansion of new kinase assay offerings to accelerate drug candidate screening and validation
March, 23
 2008 consolidated results
February, 12
 Cerep announces sales revenues for 2008
January, 7
 Cerep signs a license agreement with Théa for the development of its LFA-1 antagonist in ophthalmology

Company profile
Cerep worldwide
Cerep mission & strategy
Key management & Board
Analyst coverage
Financials
Highlights
Prospects
Key financials
Stock
News & events
Press releases
Conferences
Shareholders' info
Financial calendar
Document publicly available
Other
Financial reports
Investor contact

Français :: Home :: Site map :: Legal notice :: Credits ::